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Endovascular aneurysm repair (EVAR) has become the 
most frequently used treatment modality for infrarenal 
abdominal aortic aneurysms (AAAs) because of reduced 
early morbidity and mortality, but the benefit of EVAR over 
open repair declines after 2 years owing to endoleak, graft 
displacement, limb occlusions, stent fractures, and second-
ary ruptures.1–6 In addition to a linear pullout force, lateral 
movement of the endograft leads to endograft instability 
and late adverse events, but none of the current EVAR 
devices are designed to oppose these forces.7
The Nellix EndoVascular Aneurysm Sealing System 
(Endologix, Inc, Irvine, CA, USA) was developed in an 
attempt to reduce complications, particularly endoleaks and 
subsequent reinterventions.8 The EVAS device consists of 
dual balloon-expandable stent-grafts surrounded by endo-
bags that are filled in situ with polymer to achieve seal and 
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Abstract
Purpose: To analyze the 2-year outcomes of endovascular aneurysm sealing (EVAS) according to 2 versions of the 
instructions for use (IFU). Methods: A retrospective study was conducted involving 355 consecutive patients treated with 
the first-generation EVAS device from April 2013 to December 31, 2015, at 3 high-volume centers. Out of 355 patients 
treated with EVAS, 264 were elective asymptomatic infrarenal EVAS procedures suitable for analysis. In this cohort, 168 
(63.3%) patients were treated within the IFU 2013 criteria; of these 48 (18.2%) were in compliance with the revised IFU 2016 
version. Results: Overall technical success was 98.2% (165/168) in the IFU 2013 group and 97.9% (47/48) in the IFU 2016 
subgroup (p=0.428). The 2-year freedom from reintervention estimates were 89.7% (IFU 2013) and 95.7% (IFU 2016), with 
significantly more reinterventions in the first 45 cases (p=0.005). The stenosis/occlusion estimates were 6.5% (IFU 2013) 
and 4.2% (IFU 2016; p=0.705). Nine (5.4%) endoleaks (8 type Ia and 1 type Ib) were observed within the IFU 2013 cohort; 
3 (2.1%) were in the IFU 2016 subgroup (p=0.583). Migration ≥10 mm or ≥5 mm requiring intervention was reported in 12 
(7.1%) patients in the IFU 2013 cohort but none within the IFU 2016 subgroup. Ten (6.0%) patients demonstrated aneurysm 
growth in the IFU 2013 cohort, of which 2 (4.2%) were in the IFU 2016 subgroup. Overall survival and freedom from 
aneurysm-related death estimates at 2 years were 90.9% and 97.6% in the IFU 2013 cohort (IFU 2016: 95.5% and 100.0%). 
The prevalence of complications seemed lower within IFU 2016 without significant differences. Conclusion: This study 
shows acceptable 2-year results of EVAS used within the IFU, without significant differences between the 2 IFU versions, 
though longer follow-up is indicated. The refined IFU significantly reduced the applicability of the technique.
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anatomical fixation.9,10 Since its launch in 2013, the Nellix 
device has shown a high aneurysm exclusion rate and a low 
frequency of complications,8,11–17 but concerns exist as 
regards migration and endoleak in the long term.
Although commercially available EVAR stent-grafts 
come with device-specific instructions for use (IFU), these 
instructions are oftentimes set aside due to clinical neces-
sity and possible misjudgment of device capacities. EVAR 
studies have shown that the more the IFU are violated, the 
more the repair is prone to failure.18,19 This emphasizes the 
importance of selecting patients with proper aneurysm mor-
phology as a key determinant for successful exclusion of 
the aneurysm.
Current early results on EVAS are based on study popu-
lations consisting of patients treated within and outside the 
Nellix IFU, which could have affected results. In the begin-
ning, EVAS appeared to be applicable to a wider range of 
aneurysm morphologies than other devices then in use, 
according to the original IFU (Table 1).20 In the EVAS 
FORWARD Global IDE Trial,16 1-year safety and effective-
ness results demonstrated low morbidity and mortality and 
high procedural and treatment success. However, 2-year 
imaging revealed a signal of migration, leading to a dedi-
cated root cause analysis traced to lateral bending21,22 of the 
stents into surrounding soft thrombus. The ability of the 
stents themselves to resist bending forces is low, requiring 
polymer support. To address complications (especially 
migration but also endoleak and AAA sac growth) and 
improve outcomes, the IFU were refined in 2016 based on 
unpublished 2-year results of the EVAS IDE trial. The 
changes include a reduced maximum infrarenal neck diam-
eter and reduced degree of neck diameter change from 
≤20% to ≤10% (Table 1). Also, an aortic lumen ratio was 
added to the IFU, comparing the maximum diameter of the 
aortic aneurysm to the maximum aortic blood lumen diam-
eter. This limits the proportion of thrombus allowed in the 
aneurysm in order to provide better seal and prevent migra-
tion. Finally, distal seal criteria were made more stringent; 
the maximum iliac artery diameter was limited to 20 mm 
and a distal seal zone length was added. The aim of the pres-
ent study was to retrospectively analyze the 2-year out-
comes of the EVAS device based on the 2013 and 2016 
versions of the IFU.
Methods
Study Design
A retrospective cohort study was conducted of all patients 
treated with the first-generation Nellix (3SQ+) from April 
2013 to December 31, 2015, in 3 high-volume centers in the 
Netherlands, each performing >100 EVAS procedures 
within that time frame. Patients were eligible for this analy-
sis if they had an asymptomatic infrarenal AAA treated with 
a standard 2-component Nellix device in an elective proce-
dure. Of the 355 patients treated in the observation period, 
27 were excluded because they were treated for a sympto-
matic (n=16) or ruptured (n=11) AAA (Figure 1). Three 
more patients were excluded because of inaccurate sizing 
on magnetic resonance angiography in 3Mensio or because 
of missing preoperative computed tomography (CT) scans 
(patients referred from other centers). From the remaining 
325 patients, 61 were excluded because they were not 
treated with a regular EVAS procedure, including EVAS as 
relining after previous EVAR (n=17), unilateral EVAS 
(n=12), chimney EVAS (ch-EVAS; n=19), Nellix-in-Nellix 
application (n=3), or EVAS for an isolated CIA aneurysm 
(n=10). This left 264 asymptomatic patients electively 
treated for an infrarenal AAA in a standard EVAS proce-
dure. Ninety patients included in the analysis had been part 
of the EVAS FORWARD Global registry15 or the EVAS 
FORWARD IDE trial.16
The study was conducted according to the principles of 
the Declaration of Helsinki and in accord with the applica-
ble national guidelines, regulations, and acts. Personal data 
were anonymized and handled in compliance with the 
Dutch Personal Data Protection Act. The Dutch central eth-
ics board waived the need for informed consent for a retro-
spective review.
Patient Selection and IFU Assignment
Hospital records of the 264 patients were reviewed and rel-
evant data retrieved; comorbidities were scored according 
Table 1. Instructions for Use (IFU) for the Nellix EndoVascular 
Aneurysm Sealing System.
IFU 2013 Refined IFU 2016
Infrarenal neck length 
≥10 mm
No changea
Proximal neck diameter 
change ≤20%
≤10%
Proximal neck diameter 
18 to 32 mm
18 to 28 mm
Infrarenal neck angle 
≥60°
No change
Aneurysm blood lumen 
diameter ≤60 mm
No change
 Ratio of maximum aortic aneurysm 
diameter to maximum aortic 
blood lumen diameter <1.4
Iliac artery luminal 
diameter 9 to 35 mm
9 to 20 mm
 Distal iliac artery seal zone length 
≥10 mm with maximal 25 mm 
diameter (inner to inner wall)
Femoral access ≥7 mm No change
aDefinition for location of distal end of neck changed from 10% increase 
from the diameter of the lowest renal artery in 2013 to 20% in 2016.
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to the Society for Vascular Surgery (SVS) comorbidity 
grading scale.23 Pre- and postoperative computed tomogra-
phy angiography (CTA) scans were assessed by an indepen-
dent observer (J.T.B.) with the use of 3-dimensional (3D) 
vascular planning software (3Mensio Vascular; Pie Medical 
Imaging, Bilthoven, the Netherlands) to determine compli-
ance with the IFU 2013 and IFU 2016. Diameter measure-
ments were based on an outer to outer vessel diameter 
perpendicular to the center lumen line (CLL) or, if speci-
fied, the flow lumen diameter (excluding intraluminal 
thrombus). Aortic neck diameters and common iliac artery 
(CIA) flow lumen diameters were calculated as the mean of 
the anteroposterior and lateral diameters. The maximum 
aneurysm and CIA artery diameters and maximum aortic 
flow lumen diameter included a single measurement of the 
largest diameter perpendicular to the CLL.
The maximum aneurysm and maximum aortic flow 
lumen diameters were used to calculate the diameter ratio 
for the refined IFU 2016. Vascular access was adequate 
when the external iliac artery (EIA) diameter was >7 mm. 
The infrarenal neck length was measured by the centerline 
distance from the baseline (ie, lowest renal artery) to the 
nearest plane that shows a 20% (IFU 2013) or 10% (IFU 
2016) increase in aortic diameter over the diameter at base-
line. Suprarenal and infrarenal angulations were measured 
in accord with a previously reported standard.24 A distal seal 
zone was determined by any vessel segment in the CIA or 
EIA with an outer to outer diameter in a range of 9 to 20 mm 
and a minimum length of 10 mm within a length of 170 mm 
from the baseline, defined by the sealing length (maximum 
EVAS stent length 180 mm for the first-generation Nellix 
EVAS system). Preoperative and postoperative seal lengths 
were assessed in 3D CT analysis to determine the place-
ment of the endosystems. Of the 264 patients reviewed, 168 
(63.6%) had anatomical characteristics within the IFU 
2013, while 48 (18.2%) of these patients were within the 
refined IFU 2016. The baseline and anatomical characteris-
tics of these study groups are shown in Table 2 and a break-
down of the compliance with both IFU versions in Table 3.
EVAS Procedure and Follow-up
The EVAS procedure has been detailed previously.9 After 
antibiotic prophylaxis, bilateral femoral accesses were 
obtained either percutaneously or by surgical cutdown and 
heparin was administered. The Nellix stent-grafts were 
inserted bilaterally over stiff wires and preferably positioned 
just distal to the renal arteries. Once the sheaths were retracted, 
a vacuum was applied to test the integrity of the endobags. 
Subsequently, the balloons in the stents were inflated simulta-
neously to 7 atm. The endobags were prefilled with saline to 
verify the calculated polymer quantity and to assess the 
absence of endoleaks with the intended endobag pressure of 
180 mm Hg. The endobags were deflated, and a polyethylene 
glycol–based polymer was instilled into the endobags with a 
filling pressure aimed at 180 mm Hg while the position was 
maintained. If required a secondary fill was performed to cor-
rect insufficient sac filling.9
Various modifications in the treatment protocol were 
implemented during the observation period: (1) the intended 
endobag pressure was higher than 180 mm Hg (220–250 
mm Hg), (2) after endobag filling, the Nellix stents were 
postdilated with 10-mm balloons, and (3) the Nellix bal-
loons were left inflated during the entire procedure or rein-
flated during the curing process. These modifications were 
done to increase stability and to avoid pillowing of the 
endobags into the interior of the stent frames.
Follow-up involved outpatient clinic visits at 1 to 3 
months, 12 months, and annually thereafter unless events 
required closer examination. A window of 2 months was 
added to the 2-year follow-up, extending the total follow-up 
to 26 months to ensure no data were missed due to schedul-
ing. Follow-up consisted of clinical examination, CTA and/
or duplex ultrasound imaging, and abdominal radiography. 
In 32 patients (10 within IFU 2016), only the first postop-
erative CT scan was available.
Endpoints and Definitions
The main study endpoint was reintervention for any type of 
endoleak, device stenosis or occlusion, device migration, 
AAA growth, or device defect within 2 years of the initial 
Figure 1. Flowchart of patient exclusion and assignment 
to within or outside the original (2013) and revised (2016) 
instructions for use (IFU). Note that the IFU 2016 patients are 
a subgroup of the IFU 2013 cohort, and several patients were 
excluded based on >1 anatomical criterion (see Table 3). Ch-
EVAS, chimney endovascular aneurysm sealing; CT, computed 
tomography; EVAS, endovascular aneurysm sealing.
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procedure. The secondary outcomes were technical success, 
survival, aneurysm-related death, endoleak, limb stenosis/
occlusion, migration, and AAA growth.
The outcome measures were defined according to the 
SVS reporting standards.25 Technical success was defined as 
successful introduction and deployment of the device with-
out conversion, death, type I or III endoleak, or graft limb 
occlusion within 24 hours after the procedure. The term 
“assisted technical success” was applied to cases in which 
unplanned endovascular or surgical procedures were 
required to successfully exclude the aneurysm. Primary 
patency referred to freedom from stenosis or occlusion with-
out the need for other surgical or endovascular procedures; 
secondary patency was obtained with the use of a surgical or 
endovascular procedure after occlusion occurred.25 Based 
on the reporting standards,25 migration was defined as ≥10-
mm caudal displacement of one or both EVAS stent-grafts 
compared to the first postoperative CT or ≥5-mm migration 
that required a reintervention. In addition to migration, the 
current analysis recorded caudal movement of 5 to 10 mm.
Endoleaks were classified according to the reporting 
standards,25 but proximal type I endoleaks were subclassi-
fied using a new EVAS-specific system26: type Is1 refers to 
the appearance of contrast between the endobag and the 
wall of the proximal neck but not in continuation with 
the aneurysm sac, type Is2 is visible contrast in between the 
endobag and aneurysm wall or thrombus, and type Is3 
shows contrast or fresh thrombus in between the endobags 
inside the sac.
Aneurysm growth was assessed by >5-mm increase in 
maximum aneurysm diameter between the last available 
follow-up scan within 2 years and the first postoperative CT. 
If patients were followed by duplex ultrasound only, the 
diameter was compared to the diameter of the first postop-
erative ultrasound. Migration and caudal movement were 
reported based only on the 3D CT analysis, while endoleaks 
and aneurysm growth were reported based on all follow-up 
imaging. All endoleaks diagnosed on duplex were confirmed 
on CT. If an endoleak was witnessed on ultrasound but not 
on CT, the CT data were regarded as superior. 









 Age, y 75 (68, 79) 74 (68, 79) 75 (68.2, 79) 0.702
 Men 310 (87.3) 155 (92.3) 40 (83.3) 0.064
 ASA class 0.766
  II 199 (56.1) 107 (63.7) 29 (60.4)  
  ≥III 146 (41.1) 60 (35.7) 18 (37.5)  
  Missing 10 (2.8) 1 (0.6) 1 (2.1)  
 Hypertension 242 (68.2) 112 (66.7) 33 (68.8) 0.786
 Hyperlipidemia 267 (75.2) 126 (75.0) 38 (79.2) 0.552
 Smoking (in past 10 years) 159 (44.8) 78 (46.4) 20 (41.7) 0.559
 Cardiac disease 151 (42.5) 72 (42.9) 27 (56.3) 0.117
 Pulmonary disease 96 (27.0) 47 (28.0) 13 (27.1) 0.903
 Renal diseasec 91 (25.6) 34 (20.2) 8 (16.7) 0.581
 Diabetes mellitus 51 (14.4) 27 (16.1) 11 (22.9) 0.272
Anatomical characteristics
 Infrarenal neck diameter, mm 23.4 (24.4, 26.0) 23.3 (21.8, 25.5) 22.3 (20.9, 24.3) 0.031
 Infrarenal neck angle, deg 23.0 (12.5, 35.6) 21.9 (13.1, 35.0) 25.2 (15.2, 38.2) 0.234
 Infrarenal neck length at 10% diameter increase, mm 16 (9.8, 30.0) 18.0 (12.0, 31.0) 20.0 (15.0, 30.8) 0.548
 AAA lumen diameter, mm 40.9 (36.2, 48.3) 42.3 (37.9, 48.1) 46.6 (41.3, 50.8) 0.003
 AAA outer diameter, mm 57.7 (54.0, 62.7) 57.9 (54.3, 61.7) 56.4 (53.0, 61.2) 0.141
 Ratio AAA outer diameter to AAA lumen diameter 1.37 (1.19, 1.60) 1.35 (1.19, 1.57) 1.27 (1.15, 1.32) 0.000
 Infrarenal lumen volume, mL 78.3 (59.0, 107.1) 80.3 (64.1, 107.3) 93.6 (73.7, 110.8) 0.128
 Right CIA lumen diameter, mm 10.0 (9.0, 11.8) 10.5 (9.3, 12.0) 10.0 (9.2, 11.0) 0.054
 Right CIA outer diameter, mm 17.4 (14.3, 21.4) 18.0 (15.0, 21.4) 16.5 (14.1, 18.2) 0.002
 Left CIA lumen diameter, mm 10.0 (9.0, 11.8) 10.5 (9.3, 12.0) 10.2 (9.1, 11.0) 0.133
 Left CIA outer diameter, mm 17.1 (14.0, 20.7) 17.2 (14.8, 20.4) 16.0 (14.1, 18.1) 0.019
Abbreviations: AAA, abdominal aortic aneurysm; ASA, American Society of Anesthesiologists; CIA, common iliac artery; IFU, instructions for use.
aContinuous data are presented as the median (interquartile range Q1, Q3); categorical data are given as the counts (percentage).
bComparison between the IFUs.
cCreatinine level ≥2.4 mg/dL.
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Aneurysm-related mortality included death due to aneurysm 
rupture or the consequences of a primary or secondary pro-
cedure or surgical conversion.
Statistical Analysis
Continuous variables were presented as the mean ± stan-
dard deviation or as median and interquartile range (IQR: 
Q1, Q3) depending on the results of normalcy testing. 
Categorical variables were presented as frequencies and 
percentages. Proportions and nominal variables were com-
pared using the chi-square test or the Fisher exact test in the 
case of a small sample size. Continuous variables were 
compared by means of the independent t test or the Mann-
Whitney U test for nonparametric data.
Kaplan-Meier analysis was employed to estimate rates 
for survival, freedom from reintervention, primary and sec-
ondary patency, freedom from migration, freedom from 
AAA growth, freedom from any endoleak (type Ia/b, II, and 
III), and freedom from type Ia endoleak (Is2 and Is3). 
Curves were compared with the log-rank test. Datasets were 
truncated when the standard error exceeded 10%. The 
threshold of statistical significance was p<0.05. All statisti-
cal analyses were performed using IBM SPSS Statistics 
(version 24.0; IBM Corporation, Armonk, NY, USA).
Since this study included all patients treated within the 
IFU since the introduction of the Nellix device, a subanaly-
sis was performed to determine whether the results were 
influenced by the learning curve. Based on previous research 
showing that optimal EVAR results are achieved after 10 to 
20 cases,27 the first 15 cases (based on the date of the EVAS 
procedure) within the IFU 2013 in each center were regarded 
as the learning phase and compared with the remainder of 
cases within the IFU 2013 group. Another IFU 2013 sub-
group analysis was performed comparing the infrarenal neck 
length in those patients who experienced an endoleak, aneu-
rysm growth, migration, and/or caudal movement of 5 to 10 
mm to the patients who had no complication.
Results
There were no statistically significant differences in base-
line characteristics between the IFU 2013 patients and the 
IFU 2016 subgroup (Table 2). However, because of the 
change in anatomical requirements in 2016, significant dif-
ferences in anatomical variables were observed between the 
IFU 2013 and IFU 2016 versions. The median infrarenal 
neck diameter was 23.3 mm (IQR 21.8, 25.5) within the 
IFU 2013 and 22.3 mm (IQR 20.9, 24.3) within the IFU 
2016 (p=0.031). Also, the AAA lumen diameter (p=0.003) 
and the ratio of the AAA outer lumen diameter to AAA 
lumen diameter (p<0.001) were significantly different, as 
were the CIA outer diameters on both sides (right p=0.002 
and left p=0.019). No other significant differences between 
the IFUs were observed.
The majority of patients were operated upon under 
general anesthesia (p=0.583) with surgical cutdown of the 
CIA (p=0.782). Distal extensions were used in 15 (8.9%) 
patients in the IFU 2013 cohort, of which 7 (4.2%) were 
planned preoperatively; there was only 1 (2.1%) distal 
extension within the IFU 2016 (p=0.272) that was not 
planned preoperatively.
Overall technical success was 98.2% (165/168) in the 
IFU 2013 group and 97.9% (47/48) in the IFU 2016 sub-
group (p=0.428). Of the 9 assisted technical success cases 
in the larger cohort, 8 were due to an unplanned distal 
extension; in the other case, an endobag had lost integrity 
after the prefill and the other endobag was used to fill the 
aneurysm sac. The technical failures in both groups were 
due to postoperative proximal type Ia endoleaks. One type 
II endoleak was observed at completion angiography. All 
immediate postoperative endoleaks were not observed dur-
ing further follow-up. Access-related complications are 
Table 3. Compliance With the Nellix Instructions for Use in 
2013 and 2016 for the 264 Electively Treated Patients.a,b
Instructions for use 2013  
 Infrarenal neck 222 (84.1)
  Length ≥10 mm and ≤20% diameter change 233 (88.3)
  Diameter ≥18 mm 254 (96.2)
  Diameter ≤32 mm 244 (92.4)
  Missing data 4 (1.5)
 Infrarenal neck angle ≤60° 258 (97.7)
 Aneurysm blood lumen diameter ≥60 mm 254 (96.2)
 CIA lumen diameter 9 to 35 mm 207 (78.4)
  CIA diameter ≥9 mm 206 (78.0)
  CIA diameter ≤35 mm 264 (100.0)
  Missing data 5 (1.9)
 Access diameter >7 mm 236 (89.4)
Instructions for use 2016
 Infrarenal neck 183 (69.3)
  Length ≥10 mm and ≤10% diameter change 204 (77.3)
  Diameter ≥18 mm 254 (96.2)
  Diameter ≤28 mm 207 (78.4)
  Missing data 3 (1.1)
 Infrarenal neck angle ≤60° 258 (97.7)
 Aneurysm blood lumen diameter ≤60 mm 254 (96.2)
 Ratio of maximum aneurysm diameter to 
maximum blood lumen diameter <1.4
149 (56.4)
 CIA lumen diameter 9 to 35 mm 207 (78.4)
  CIA diameter ≥9 mm 206 (78.0)
  CIA diameter ≤35 mm 264 (100.0)
  Missing data 5 (1.9)
 Distal iliac artery seal (length ≥10 mm and 
outer diameter 9 to 20 mm)
167 (63.3)
 Access diameter >7 mm 236 (89.4)
Abbreviation: CIA, common iliac artery.
aData are presented as the count (percentage).
bNote that some of the patients were out of compliance with >1 criterion.
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shown in Table 4. One patient had renal function deteriora-
tion not requiring dialysis after protrusion of the endobag 
over a renal artery. No other adverse events were observed 
during the hospital stay.
Outcomes at 30 Days and in Follow-up
In both IFU groups the median follow-up was 23 months 
(IFU 2013 IQR: 12, 26; IFU 2016 IQR 12, 29; p=0.495). At 
1 year, 119 of the 168 IFU 2013 patients and 26 of the 48 
IFU 2016 patients were present for follow-up. Seventy of 
the IFU 2013 patients and 23 of the IFU 2016 patients had 
≥2 years of follow-up. Within the entire cohort the median 
follow-up was 18 months (IQR 11, 24). The available imag-
ing modality at each follow-up period for the IFU 2013 
cohort is reported in Table 5.
Reinterventions. During the 2-year follow-up, a total of 
19 (11.3%) patients required a reintervention in the IFU 
2013 group vs 4 (8.3%) in the IFU 2016 subgroup (p=0.555; 
Table 6). Three (1.8%) IFU 2013 patients had a reinterven-
tion within 30 days for occlusions or stenoses, including a 
femoral-femoral bypass, thrombectomy and relining of the 
endoprosthesis, and thrombectomy of the Nellix system in 
combination with common femoral artery endarterectomy. 
One (2.1%) patient in the revised IFU group required a fem-
oral-femoral bypass.
Of the 7 reinterventions performed between 30 days 
and 1 year, 1 (2.1%) was in the IFU 2016 group (throm-
bectomy with relining) and 6 (3.6%) were in the IFU 2013 
group (1 thrombectomy with relining, 2 thrombectomies 
with iliac extension/stenting, 1 thrombolysis with iliac 
stenting, 1 relining of both EVAS stents for iliac stenosis, 
and 1 conversion to open repair due to an aortoenteric fis-
tula 3 months after the EVAS procedure).
At 2-year follow-up, 10 (6.0%) additional reinterven-
tions were performed within the IFU 2013 cohort, including 
relining for a stenosis, femoral-femoral bypass for occlu-
sion, embolization for a type Ia endoleak, and 2 Nellix-in-
Nellix proximal extensions for a secondary rupture and a 
migration, respectively. The other 5 IFU 2013 patients 
underwent conversion to open repair owing to type Ia 
endoleak with migration at 24 months, sac expansion at 15 
months, periaortitis at 22 months, and 2 for type Ia endoleak 
at 13 and 24 months. Two of the reinterventions for type Ia 
endoleak (embolization and conversion) involved patients 
in the IFU 2016 subgroup. In total, 6 conversions to open 
repair were performed within the 2-year period after the pri-
mary Nellix procedure.
The freedom from reintervention estimates were 94.4% 
(95% CI 90.9% to 97.9%) and 89.7% (95% CI 84.4% to 
95.0%) at 1 and 2 years for the 2013 IFU and 95.7% (95% 
CI 90.0% to 100%) for both time points in the 2016 IFU 
subgroup, respectively (p=0.342; Figure 2A).
Stenosis/occlusion. There were 11 (6.5%) patients with a 
symptomatic stenosis or occlusion (Table 6) during the 
2-year follow-up in the IFU 2013 group and 2 (4.2%) in the 
IFU 2016 subgroup (p=0.705). Five (3.0%) occlusions (2 in 
IFU 2016 patients) and 1 (0.6%) symptomatic stenosis were 
observed at ≤30 days. Two of these patients presented with 
a reocclusion at 1 year and both were treated with relining 
using a self-expanding covered stent. At 1 year, there were 
2 new-onset symptomatic stenoses and 1 new-onset occlu-
sion; all underwent a reintervention. At 2 years there were 2 
new-onset occlusions reported. One patient was planned for 
a reintervention, but this was not yet performed within 26 
months. The other patient with an occlusion was considered 
high risk for reintervention and was treated conservatively 
with physical therapy. Overall, all but 2 patients with a 
symptomatic stenosis or occlusion received a 
reintervention.
The primary patency estimates for the IFU 2013 cohort 
were 96.4% (95% CI 93.7% to 99.1%) and 94.0% (95% 
CI 89.7% to 98.3%) at 1 and 2 years, respectively (Figure 
2B); for the IFU 2016 subgroup both estimates were 
95.8% (95% CI 90.1% to 100%; p=0.846). The secondary 
patency estimates were 100% at 1 year and 97.6% (95% 
CI 94.5% to 100%) at 2 years for the IFU 2013 patients 
and 100% at both time points for the IFU 2016 subgroup 
(p=0.432).







 Anesthesia (general) 143 (85.1) 36 (75.0) 0.583
 CIA cutdown 164 (97.6) 46 (95.8) 0.782
 Blood loss, mL 130 (100, 300) 150 (63, 300) 0.939
 Duration, min 90 (70, 108) 90 (74, 106) 0.915
 Hospital stay, d 3 (3, 4) 3 (3, 4) 0.323
 Technical success 165 (98.2) 47 (97.9) 0.428
  Primary 156 (92.9) 46 (95.8)  
  Assisted 9 (5.4) 1 (2.1)  
Complications
 Type Ia endoleaks 3 (1.8) 1 (2.1)  
 Renal 1 (0.6) 1 (2.1)  
 Access-related
  Groin hematoma 11 (6.5) 4 (8.3) 0.437
  Groin swelling 8 (4.8) 4 (8.3) 0.264
  Neuralgia 8 (4.8) 1 (2.1) 0.367
  Wound leak 2 (1.2) 0 0.604
  Wound infection 2 (1.2) 1 (2.1) 0.531
Abbreviations: CIA, common iliac artery; IFU, instructions for use.
aContinuous data are presented as the median (interquartile range Q1, 
Q3); categorical data are given as the counts (percentage).
bComparison between the IFUs.
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Endoleak. Overall, 9 (5.4%) endoleaks (Table 6) were 
observed in the IFU 2013 cohort during the 2-year follow-
up, of which 3 (2.1%) were in the IFU 2016 subgroup 
(p=0.583). Four endoleaks were found between 30 days and 
1 year within the IFU 2013 cohort and another 5 between 1 
and 2 years. One endoleak was seen between 30 days and 1 
year and 2 endoleaks were seen between 1 and 2 years in the 
IFU 2016 subgroup. At 2 years, 5 of 9 endoleaks had 
received a reintervention as detailed previously. The free-
dom from any endoleak estimates (Figure 2C) at 1 and 2 
years were 97.4% (95% CI 95.2% to 99.9%) and 92.7% 
(95% CI 87.6% to 97.8%), respectively, for the IFU 2013 
cohort and 97.8% (95% CI 93.5% to 100%) and 90.1% 
(95% CI 78.9% to 100%) for the IFU 2016 subgroup 
(p=0.708). Freedom from type Ia endoleak estimates at the 
same time points were 98.0% (95% CI 95.8% to 100%) and 
93.3% (95% CI 88.2% to 98.4%) for the patients in the IFU 
2013 group and 97.8% (95% CI 93.5% to 100%) and 90.1% 
(95% CI 78.9% to 100%) for the IFU 2016 subgroup 
(p=0.577).
Migration. In follow-up there were 12 (7.1%) IFU 2013 
patients demonstrating migration (9 cases ≥10 mm and 3 
<10 mm requiring conversion). Two of the 12 were observed 
at 1 year and the remaining 10 between 1 and 2 years. 
Among the 9 IFU 2013 cases with migration >10 mm, 4 
had a proximal endoleak; 3 of the 4 had aneurysm growth 
>5 mm.
Caudal movement between 5 and 10 mm was observed in 
25 (14.9%) patients within the IFU 2013 group and 4 (8.3%) 
within the IFU 2016 subgroup (p=0.241). The 3 cases requir-
ing a reintervention were described above. Between 30 days 
and 1 year, 10 cases of caudal movement were observed in 
the IFU 2013 cohort (4 in the IFU 2016 subgroup). The 
remaining 15 IFU 2013 cases of caudal movement were 
observed between 1 year and 2 years. The freedom from 
migration estimates (Figure 2D) were 98.3% (95% CI 95.9% 
Table 5. Imaging Modality per Follow-up Period for the Patients Within the 2013 Nellix Instructions for Use.a
Type of Imaging
0 to 6 Months 
(n=168)
6 to 12 Months 
(n=157)
12 to 18 Months 
(n=138)
18 to 24 Months 
(n=107)
CTA 57 (33.9) 34 (21.7) 35 (25.4) 31 (29.0)
CTA and duplex 40 (23.8) 14 (8.9) 10 (7.2) 9 (8.4)
CTA and radiography 10 (6.0) 3 (1.9) 4 (2.9) 2 (1.9)
CTA, duplex, and radiography 42 (25.0) 19 (12.1) 11 (8.0) 9 (8.4)
Duplex 13 (7.7) 31 (19.7) 19 (13.8) 18 (16.8)
Duplex and radiography 0 (0) 5 (3.2) 2 (1.5) 1 (0.9)
Missing data 6 (3.6) 51 (32.5) 57 (41.3) 37 (34.6)
aData are presented as the count (percentage).
Abbreviations: CTA, computed tomography angiography.
Table 6. Outcomes for Different Follow-up Periods and Both IFU Cohorts.a
Outcome
<30 Days 30 Days to 1 Year 1 to 2 Years
IFU 2013 (n=168) IFU 2016 (n=48) IFU 2013 (n=119) IFU 2016 (n=26) IFU 2013 (n=70) IFU 2016 (n=23)
Reinterventions 3 (1.8) 1 (2.1) 6 (5.0) 1 (3.8) 10 (14.3) 2 (8.7)
 Conversions — — 1 (0.8) — 5 (7.1) 1 (4.3)
Occlusion 5 (3.0) 2 (4.2) 1 (0.8) — 2 (2.9) —
Stenosis 1 (0.6) — 2 (1.7) — — —
Endoleakb
 Type Is2 3 (1.8)c 1 (2.1)c 2 (1.7) 1 (3.8) 3 (4.3) —
 Type Is3 — — 1 (0.8) — 2 (2.9) 2 (8.7)
 Type Ib — — 1 (0.8) — — —
 Type II 1 (0.6)c — — — — —
Migration — — 2 (1.7) — 10 (14.3) —
Caudal movement — — 10 (8.4) 4 (15.4) 15 (21.4)  
Sac growth — — 2 (1.7) — 6 (8.6) 2 (8.7)
Abbreviations: IFU, instructions for use.
aData are presented as the count (percentage).
bAccording to van den Ham et al.24
cThese intraoperative leaks were not visible on postoperative imaging.
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Figure 2. Kaplan-Meier analyses of (A) freedom from reintervention, (B) primary patency, (C) freedom from any endoleak, (D) 
freedom from migration, (E) freedom from aneurysm growth, and (F) overall survival. The standard error did not exceed 10% at any 
time point in all curves.
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to 100%) at 1 year and 89.9% (95% CI 83.0% to 96.8%) at 2 
years in the IFU 2013 cohort and 100% at both time points 
for the IFU 2016 subgroup (p=0.150).
Patients having migration or caudal movement in combi-
nation with endoleak and/or sac growth are described in 
Table 7. Endoleak was found in conjunction with 5- to 
10-mm caudal movement in 7 (4.2%) patients; 5 also had 
aneurysm growth. All cases with caudal movement in com-
bination with endoleak and/or aneurysm growth were 
within IFU 2013 but not within IFU 2016.
Aneurysm Growth
Ten (6.0%) patients demonstrated aneurysm growth in the 
IFU 2013 cohort, of which 2 (4.2%) were in the IFU 2016 
subgroup. No aneurysm growth was seen within 30 days. 
Only 2 cases were observed between 30 days and 1 year 
(IFU 2013); the remaining 8 were between 1 and 2 years 
(Table 6). Freedom from aneurysm growth estimates 
(Figure 2E) were 97.9% (95% CI 95.5% to 100%) and 
91.8% (95% CI 86.5% to 97.1%) at 1 and 2 years, respec-
tively, in the IFU 2013 cohort and 100% and 89.3% (95% 
CI 77.7% to 100%), respectively, in the IFU 2016 subgroup 
(p=0.843).
Survival
During the observation period, 14 (8.3%) patients died (1 at 
30 days, 6 at 1 year, and 7 at 2 years) within the IFU 2013 
cohort; 4 (8.3%) were in the IFU 2016 subgroup (2 at 30 
days and 2 at 1 year). Of the 4 (2.4%) aneurysm-related 
deaths, 1 patient suffered a hemorrhagic stroke on day 16, 
the patient with an aortoenteric fistula at 3 months suc-
cumbed to acute renal failure and bacteremia after conver-
sion, the patient with secondary rupture died after conversion 
to open repair following an unsuccessful Nellix-in-Nellix 
procedure, and a fourth patient died due to poor cardiac 
condition after open repair for a type Ia endoleak (this 
patient was within both IFUs). Other causes for death were 
cardiac illness (n=3), cancer (n=2), cerebral bleeding (n=1), 
bowel ischemia (n=1), dementia and pneumonia (n=1), and 
2 unknown causes.
The overall survival estimates (Figure 2F) at 1 and 2 
years were 95.5% (95% CI 92.2% to 98.8%) and 90.9% 
(95% CI 86.5% to 96.0%), respectively, in the IFU 2013 
cohort and 95.5% (95% CI 89.4% to 100%) at both time 
points in the IFU 2016 subgroup (p=0.472). The freedom 
from aneurysm-related mortality estimates were 98.8% 
(95% CI 97.0% to 100%) and 97.6% (95% CI 94.9% to 
100%) at 1 and 2 years in the 2013 cohort and 100% for 
both time points in the 2016 subgroup (p=0.351).
Learning Curve and Seal Length Subanalyses
When comparing the first 15 cases within IFU 2013 in each 
center [n=45; median follow-up 30 months (IQR 23, 35)] to 
the remaining cases [n=123; follow-up 18 months (IQR 12, 
24)], significantly more reinterventions were seen in the 
first group [6 (13.3%) vs 9 (7.3%), p=0.005], largely due to 
stenoses/occlusions. No significant difference between the 
early phase and the later phases was seen regarding the rate 
of any endoleak (p=0.098), migration (p=0.259), aneurysm 
growth (p=0.094), stenosis or occlusion (p= 0.347), or death 
(p=0.371).
The median infrarenal neck length prior to EVAS was 18 
mm (IQR 12, 31) in the IFU 2013 group and 20 mm (IQR 
15, 31) in the IFU 2016 subgroup. Seal length after EVAS, 
however, was 14 mm in both groups (IFU 2013 IQR 7, 25; 
IFU 2016 IQR 11, 24). Examining the influence of seal 
length on complications, the infrarenal neck length prior to 
EVAS was 21 mm (IQR 12, 32) in the cohort without a 
complication vs 16 mm (IQR 13, 23) in the group with a 
complication (p=0.084). The corresponding proximal seal 
lengths after EVAS were 14 mm (IQR 6.5, 27) when no 
complication was observed and 11 mm (IQR 7, 18) when a 
complication was present (p=0.068).
Discussion
The present study shows that EVAS applied according to the 
2013 and 2016 IFUs achieved acceptable clinical results at 
up to 2-year follow-up. However, the revised IFU signifi-
cantly reduced the applicability of the technique. Among the 
264 elective EVAS procedures analyzed in this study a mere 
18% met the current anatomical characteristics of the IFU 
2016. Furthermore, a remarkable number of Nellix devices 
were deployed outside both IFUs in our cohort. Though 
these were not analyzed, several reasons may have led to the 
use of EVAS in these patients, including ch-EVAS in patients 
not suitable for fenestrated EVAR, patients not fit for open 
repair, or patients with failed EVAR. Results in the patients 
outside the IFUs may well differ from the current study 
groups. Besides the change in IFU, several modifications in 
the procedure protocol were implemented during the study 
Table 7. Distal Migration and Caudal Movement in 






Aneurysm growth and endoleak 2 2
Endoleak (no aneurysm growth) 1 1
Aneurysm growth (no endoleak) 3 4
Neither aneurysm growth nor endoleak 6 18
Total 12 25
aDistal migration refers to movement >10 mm or ≥5 mm with 
reintervention for migration; caudal movement refers to 5- to 10-mm 
migration.
Zoethout et al 279
at different time points in the 3 centers. For these reasons, 
the study groups were not entirely homogeneous despite the 
patients being within the IFU. Moreover, because of the 
small number of patients within the IFU 2016 subgroup and 
the relatively short duration of follow-up, the results from 
this cohort should be interpreted with caution.
Previous studies on EVAS report reintervention rates of 
0% to 12%,8,11–17 and a meta-analysis of reinterventions 
after EVAR showed reintervention rates ranging from 1.9% 
to 11.6%28 during a follow-up of up to 6 years; our reinter-
vention data are in line with both. The 6 cases of conversion 
in the IFU 2013 cohort might suggest that complications 
after EVAS may require another approach compared to 
sequelae after EVAR. This may be particularly true in a cen-
ter’s early experience when treatment options for complica-
tions still needed to be explored. The reintervention rate in 
our study was also influenced by the learning curve, with a 
significant reduction in reinterventions after the first 15 
cases.
Apart from a learning curve, technical maturation likely 
contributed to better outcomes. The current technique dif-
fers considerably from the procedure that was applied when 
the EVAS device was just introduced into practice. The 
Nellix balloons are currently reinflated during the curing of 
the polymer or left inflated throughout the procedure. These 
enhancements have been introduced to avoid thromboem-
bolic complications and enlarge the flow lumen by prevent-
ing pillowing. In addition, the need to use the entire 
infrarenal neck is appreciated nowadays but was not in the 
early phase of the observation period. This was reflected in 
our cohort by only a part of the available neck length being 
used for seal. Notably, patients with a seal-related compli-
cation had a shorter seal length, although this was not statis-
tically significant. However, the calculated seal length in 
the current study could be an overestimation as it suggests 
an optimal circumferential wall apposition of the endobags. 
Further studies examining the endobag position instead of 
the stent position are indicated. The learning curve and 
improvement of best practice should be taken into account 
when interpreting the results.
Evaluation of endoleak, migration, and AAA growth 
after a Nellix procedure can be challenging. Holden et al29 
described that a type I endoleak may be very subtle due to 
the device design and difficult to differentiate from calci-
fied atheromatous plaque or contrast in the endobag. Even 
though duplex is a valuable tool, CTA imaging remains the 
gold standard, partly because migration is hard to evaluate 
on duplex. Additionally, noncontrast and arterial phase CT 
studies must be obtained to ensure optimal evaluation of 
the endoleak. A retrospective 3D analysis of CT was per-
formed to ensure all endoleaks were detected; the results 
were discussed with the research group, which enabled 
scoring of the endoleaks according to a new classification 
that is not yet in common practice.26 In accordance with 
previous EVAS studies, type Ia was the predominant type 
of endoleak, while other types were extremely rare. This 
may be due to the fact that the endobags completely fill the 
aneurysm, reducing the risk of a type II endoleak, which is 
the most prevalent endoleak after EVAR. Proximal endole-
aks were treated by embolization, proximal Nellix-in-
Nellix extensions, or conversion. The durability of 
embolization30 and Nellix-in-Nellix proximal extensions31 
remains to be shown.
The majority of migration cases were identified 
between 1 and 2 years, which shows that migration is a 
problem that occurs later in follow-up. Caudal movement 
of 5 to 10 mm was observed in 15% of the patients; 
whether this caudal movement is self-limiting or leads to 
progressive migration remains to be shown. However, it is 
known that migration >10 mm is a risk factor for other 
complications.32 England et al33 showed caudal migration 
≥4 mm in 6 (17%) of 35 Nellix stent-grafts at 1 year in a 
small cohort of 18 patients, but no sequelae were men-
tioned. Spanos et al34 reported post-EVAR migration of ≥5 
mm in 8.6% of cases and 6.3% when a definition of 10 mm 
or more was used. Within their 36-month follow-up, 
22.4% of patients with migration presented with a type Ia 
endoleak. These observations emphasize the need for lon-
ger follow-up with 3D reconstructed CTA to enable clini-
cians to evaluate migration thoroughly, and follow-up 
should be standardized, including a noncontrast CT, to 
ensure endoleaks are observed if present.
The overall 8.9% mortality in this study is in accord with 
previous research (0.7%–9.5%8,11–17) despite a longer fol-
low-up. One patient died due to multiorgan failure after 
undergoing a conversion to open repair for an aortoenteric 
fistula, which is an interesting complication of EVAS. 
Currently, the available evidence does not reflect a higher 
incidence of aortoenteric fistula after EVAS11,15–17 com-
pared with EVAR. However, experience is still limited, and 
the incidence of fistula is too low to relate this to a statisti-
cally powerful conclusion.
It appears that the refined 2016 IFU does not clearly lead 
to a better outcome after the EVAS procedure compared to 
the 2013 IFU. Although not statistically significant, the 
prevalence of complications was lower in the IFU 2016 
group. However, this may be related to the small sample 
size in the IFU 2016 cohort. There were no significant dif-
ferences in the incidence of endoleak and aneurysm growth 
between both IFUs, and there were no migrations observed 
in the 2016 cohort. Nevertheless, the data may not reflect 
current practice since a second-generation device was intro-
duced in April 2016. One of the major changes is that the 
endobag is now attached not only proximally but also dis-
tally. In the first-generation device the distal part of the 
endobag could migrate proximally during deployment, and 
insufficient distal seal is considered one of the root causes 
of aneurysm growth.35
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Limitations
This was a retrospective study with data collected as avail-
able, and therefore some data were missing. The small sam-
ple size of the IFU 2016 group might be a cause for bias, 
and the median follow-up duration in this study was 23 
months. All CT scans were assessed by a single researcher 
with an extensive experience in post-EVAS imaging using 
core laboratory protocols that have been shown to have a 
very good interobserver variability.36 In addition, all com-
plications were studied by 3 vascular surgeons to improve 
the quality of data. In some cases, the latest available imag-
ing modality was duplex ultrasound, so some cases of 
migration might have been missed. The study comprised all 
patients, including the first EVAS procedures, in the 3 sites 
so a learning curve effect is likely. Also, this research 
includes solely the outcomes of the Nellix device when 
used within the IFU. Likely, this study presents more posi-
tive results as compared to the entire cohort, but this goes 
beyond the scope of this study.
Conclusion
The present study showed that EVAS applied within the 
IFU has acceptable 2-year results, but longer follow-up and 
a larger sample size are clearly indicated. The refined IFU 
significantly reduced the applicability of the technique.
Declaration of Conflicting Interests
The author(s) declared the following potential conflicts of interest 
with respect to the research, authorship, and/or publication of this 
article: Jean-Paul P. M. de Vries, Michel M. P. J. Reijnen, and Jan 
M. M. Heyligers are consultants to Endologix.
Funding
The author(s) disclosed receipt of the following financial support 
for the research, authorship, and/or publication of this article: This 
work was supported by Endologix, Inc.
ORCID iD
Michel M. P. J. Reijnen  https://orcid.org/0000-0001-7641-1322
References
 1. Acosta S, Ogren M, Bengtsson H, et al. Increasing incidence 
of ruptured abdominal aortic aneurysm: a population-based 
study. J Vasc Surg. 2006;44:237–243.
 2. Brown LC, Powell JT. Risk factors for aneurysm rupture 
in patients kept under ultrasound surveillance. UK Small 
Aneurysm Trial Participants. Ann Surg. 1999;230:289–296.
 3. Schermerhorn M, O’Malley J, Jhaveri A, et al. Endovascular 
vs. open repair of abdominal aortic aneurysms in the Medicare 
population. N Engl J Med. 2008;358:464–474.
 4. Elkouri S, Gloviczki P, McKusick MA, et al. Perioperative 
complications and early outcome after endovascular and open 
surgical repair of abdominal aortic aneurysms. J Vasc Surg. 
2004;39:497–505.
 5. United Kingdom EVAR Trial Investigators,Greenhalgh RM, 
Brown LC, et al. Endovascular versus open repair of abdomi-
nal aortic aneurysm. N Engl J Med. 2010;362:1863–1871.
 6. Greenhalgh RM, Brown LC, Kwong GP, et al. Comparison 
of endovascular aneurysm repair with open repair in patients 
with abdominal aortic aneurysm (EVAR trial 1), 30-day oper-
ative mortality results: randomised controlled trial. Lancet. 
2004;364:843–848.
 7. Figueroa CA, Taylor CA, Yeh V, et al. Effect of curva-
ture on displacement forces acting on aortic endografts: a 
3-dimensional computational analysis. J Endovasc Ther. 
2009;16:284–294.
 8. Donayre CE, Zarins CK, Krievins DK, et al. Initial clinical 
experience with a sac-anchoring endoprosthesis for aortic 
aneurysm repair. J Vasc Surg. 2011;53:574–582.
 9. Batagini NC, Hardy D, Clair DG, et al. Nellix EndoVascular 
Aneurysm Sealing System: Device description, technique 
of implantation, and literature review. Semin Vasc Surg. 
2016;29:55–60.
 10. van den Ham LH, Zeebregts CJ, de Vries JP, et al. Abdominal 
aortic aneurysm repair using Nellix EndoVascular Aneurysm 
Sealing. Surg Technol Int. 2015;26;226–231.
 11. Böckler D, Holden A, Thompson M, et al. Multicenter Nellix 
EndoVascular Aneurysm Sealing system experience in aneu-
rysm sac sealing. J Vasc Surg. 2015;62:290–298.
 12. Krievins DK, Holden A, Savlovskis J, et al. EVAR using the 
Nellix sac-anchoring endoprosthesis: treatment of favourable and 
adverse anatomy. Eur J Vasc Endovasc Surg. 2011;42:38–46.
 13. Brownrigg JR, de Bruin JL, Rossi L, et al. Endovascular 
aneurysm sealing for infrarenal abdominal aortic aneurysms: 
30-day outcomes of 105 patients in a single centre. Eur J Vasc 
Endovasc Surg. 2015;50:157–164.
 14. Zerwes S, Nurzai Z, Leissner G, et al. Early experience with the 
new endovascular aneurysm sealing system Nellix: first clini-
cal results after 50 implantations. Vascular. 2016;24:339–347.
 15. Thompson MM, Heyligers JM, Hayes PD, et al, for 
the EVAS FORWARD Global Registry Investigators. 
Endovascular aneurysm sealing: early and midterm results 
from the EVAS FORWARD Global Registry. J Endovasc 
Ther. 2016;23:685–692.
 16. Carpenter JP, Cuff R, Buckley C, et al.; Nellix Investigators. 
One-year pivotal trial outcomes of the Nellix system for endo-
vascular aneurysm sealing. J Vasc Surg. 2017;65:330–336.e4
 17. Gossetti B, Martinelli O, Ferri M, et al; IRENE Group 
Investigators. Preliminary results of endovascular aneu-
rysm sealing from the multicenter Italian Research on Nellix 
Endoprosthesis (IRENE) study [published online December 
11, 2017]. J Vasc Surg. doi:10.1016/j.jvs.2017.09.032.
 18. Torsello G, Troisi N, Donas KP, et al. Evaluation of the 
Endurant stent graft under instructions for use vs off-label 
conditions for endovascular aortic aneurysm repair. J Vasc 
Surg. 2011;54:300–306.
 19. Abruzzesse TA, Kwolek CJ, Brewster DC, et al. Outcomes 
following endovascular abdominal aortic aneurysm repair 
(EVAR): an anatomic and device-specific analysis. J Vasc 
Surg. 2008;48:19–28.
Zoethout et al 281
 20. Karthikesalingam A, Cobb RJ, Khoury A, et al. The morpho-
logical applicability of a novel endovascular aneurysm seal-
ing (EVAS) system (Nellix) in patients with abdominal aortic 
aneurysms. Eur J Vasc Endovasc Surg. 2013;46:440–445.
 21. Dorweiler B, Boedecker C, Dünschede F, et al. Three-
dimensional analysis of component stability of the Nellix 
endovascular aneurysm sealing system after treatment of 
infrarenal abdominal aortic aneurysms. J Endovasc Ther. 
2017;24:201–209.
 22. van Veen R, van Noort K, Schuurmann RCL, et al. 
Determination of stent frame displacement after endovascular 
aneurysm sealing. J Endovasc Ther. 2018;25:52–61.
 23. Stoner MC, Calligaro KD, Chaer FA, et al. Reporting stan-
dards of the Society for Vascular Surgery for endovascular 
treatment of chronic lower extremity peripheral artery dis-
ease. J Vasc Surg. 2016;64:e1–e21.
 24. Ouriel K, Tanquilut E, Greenberg RK, et al. Aortoiliac mor-
phologic correlations in aneurysms undergoing endovascular 
repair. J Vasc Surg. 2003;38:323–328.
 25. Chaikof EL, Blankensteijn JD, Harris PL, et al. Reporting 
standards for endovascular aortic aneurysm repair. J Vasc 
Surg. 2002;35:1048–1060.
 26. van den Ham LH, Holden A, Savlovskis J, et al; EVAS Type IA 
Endoleak Study Group. Occurrence and classification of proxi-
mal type I endoleaks after endovascular aneurysm sealing using 
the Nellix device. Eur J Vasc Endovasc Surg. 2017;54:729–736.
 27. Forbes TL, DeRose G, Lawlor DK, et al. The association 
between a surgeon’s learning curve with endovascular aortic 
aneurysm repair and previous institutional experience. Vasc 
Endovascular Surg. 2007;41:14–18.
 28. Nordon IM, Karthikesalingam A, Hinchliffe RJ, et al. 
Secondary interventions following endovascular aneurysm 
repair (EVAR) and the enduring value of graft surveillance. 
Eur J Vasc Endovasc Surg. 2010;39:547–554.
 29. Holden A, Savlovskis J, Winterbottom A, et al. Imaging after 
Nellix endovascular aneurysm sealing: a consensus docu-
ment. J Endovasc Ther. 2016;23:7–20.
 30. Donselaar EJ, Holden A, Zoethout AC, et al. Feasibility 
and technical aspects of proximal Nellix-in-Nellix exten-
sion for late caudal endograft migration. J Endovasc Ther. 
2017;24:210–217.
 31. Ameli-Renani S, Morgan RA. Transcatheter embolisation of 
proximal type I endoleaks following endovascular aneurysm 
sealing (EVAS) using the Nellix device: technique and out-
comes. Cardiovasc Intervent Radiol. 2015;38:1137–1142.
 32. Lee JT, Lee J, Aziz I, et al. Stent-graft migration following 
endovascular repair of aneurysms with large proximal necks: 
anatomical risk factors and long-term sequelae. J Endovasc 
Ther. 2002;9:652–664.
 33. England A, Torella F, Fisher RK, et al. Migration of the Nellix 
endoprosthesis. J Vasc Surg. 2016;64:306–312.
 34. Spanos K, Karathanos C, Saleptsis V, et al. Systematic review 
and meta-analysis of migration after endovascular abdominal 
aortic aneurysm repair. Vascular. 2016;24:323–336.
 35. Krievins DK, Savlovskis J, Holden AH, et al. Preservation 
of hypogastric flow and control of iliac aneurysm size 
in the treatment of aortoiliac aneurysms using the Nellix 
EndoVascular Aneurysm Sealing endograft. J Vasc Surg. 
2016;64:1262–1269.
 36. Boersen JT, van den Ham LH, Heyligers JM, et al. 
Validation of pre-procedural aortic aneurysm volume cal-
culations to estimate procedural fill volume of endobags in 
endovascular aortic sealing. J Cardiovasc Surg (Torino). 
2017;58:674–679.
